LLY

1,014.8

-0.06%↓

JNJ

230.4

+0.37%↑

ABBV

213.61

-0.27%↓

UNH

383.39

-1.88%↓

AZN

187.85

+1.77%↑

LLY

1,014.8

-0.06%↓

JNJ

230.4

+0.37%↑

ABBV

213.61

-0.27%↓

UNH

383.39

-1.88%↓

AZN

187.85

+1.77%↑

LLY

1,014.8

-0.06%↓

JNJ

230.4

+0.37%↑

ABBV

213.61

-0.27%↓

UNH

383.39

-1.88%↓

AZN

187.85

+1.77%↑

LLY

1,014.8

-0.06%↓

JNJ

230.4

+0.37%↑

ABBV

213.61

-0.27%↓

UNH

383.39

-1.88%↓

AZN

187.85

+1.77%↑

LLY

1,014.8

-0.06%↓

JNJ

230.4

+0.37%↑

ABBV

213.61

-0.27%↓

UNH

383.39

-1.88%↓

AZN

187.85

+1.77%↑

Home・Aandelen Lijst・Design Therapeutics Inc

Design Therapeutics Inc

Open

11.17 6.18

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.47

Max

11.48

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.6M -18M
EPS	-0.29
Werknemers	54
EBITDA	-1.5M -20M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+71.96% upside

Dividenden
By Dow Jones
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	98M 898M
Vorige openingsprijs	4.99
Vorige sluitingsprijs	11.17

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

3.26 / 3.63 Steun & Weerstand

Design Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 mei 2026, 20:36 UTC

Acquisities, Fusies, Overnames

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 mei 2026, 23:34 UTC

Marktinformatie

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 mei 2026, 23:28 UTC

Marktinformatie

Winsten

Global Forex and Fixed Income Roundup: Market Talk

19 mei 2026, 23:28 UTC

Marktinformatie

Winsten

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 mei 2026, 23:10 UTC

Marktinformatie

Global Equities Roundup: Market Talk

19 mei 2026, 23:10 UTC

Marktinformatie

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 mei 2026, 22:02 UTC

Winsten

ZTO Express (Cayman): Di Xu to Resign From Board

19 mei 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 mei 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 mei 2026, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 mei 2026, 21:37 UTC

Winsten

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 mei 2026, 21:31 UTC

Acquisities, Fusies, Overnames

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 mei 2026, 21:01 UTC

Winsten

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 mei 2026, 20:58 UTC

Winsten

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 mei 2026, 20:46 UTC

Populaire aandelen

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 mei 2026, 20:43 UTC

Marktinformatie

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 mei 2026, 20:34 UTC

Winsten

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 mei 2026, 20:32 UTC

Winsten

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 mei 2026, 20:32 UTC

Winsten

James Hardie Industries 4Q EPS 5c >JHX

19 mei 2026, 20:32 UTC

Winsten

James Hardie Industries 4Q Sales $1.4B >JHX

19 mei 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Analog Devices to Buy Empower Semiconductor for $1.5B

19 mei 2026, 20:18 UTC

Marktinformatie

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 mei 2026, 20:13 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

19 mei 2026, 20:13 UTC

Marktinformatie

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 mei 2026, 20:03 UTC

Acquisities, Fusies, Overnames

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 mei 2026, 20:03 UTC

Acquisities, Fusies, Overnames

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 mei 2026, 20:02 UTC

Acquisities, Fusies, Overnames

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 mei 2026, 20:02 UTC

Acquisities, Fusies, Overnames

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 mei 2026, 19:23 UTC

Marktinformatie

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Peer Vergelijking

Prijswijziging

Design Therapeutics Inc Prognose

Koersdoel

By TipRanks

71.96% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 18.4 USD 71.96%

Hoogste 22 USD

Laagste 14 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Design Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Design Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.26 / 3.63Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.